Phosphorylation of IκBα at Ser-32 by TOPK is essential for chemoresistance against doxorubicin in cervical cancer cells*

Jung-Hwan park¹⁴, Dae-Sung Yoon²⁴, Hye-Jin Choi¹⁴, Dae-Hyun Hahm³, and Sang-Muk Oh¹

¹From the Department of Biochemistry, College of Medicine, Konyang University, Daejeon 302-718, Korea

²Department of Surgery, College of Medicine, Konyang University, Konyang Hospital, Daejeon, Korea

³Acupuncture and Meridian Science Research Center, College of Oriental Medicine, Kyung Hee University, Seoul 130-701, Korea

*Running title: Role of TOPK in chemoresistance to doxorubicin-mediated apoptosis

To whom correspondence should be addressed: Sang-Muk Oh, Department of Biochemistry, College of Medicine, Konyang University, 685 Gasuwon-dong, Seo-gu, Daejeon 302-718, Korea. Phone: +82-42-600-6454; Fax: +82-42-600-6450; E-mail: sangmuk_oh@konyang.ac.kr

Keywords: TOPK; caspase; NF-κB; apoptosis

Background: The regulatory mechanism of TOPK underlying cancer cell survival remains unknown.

Results: TOPK directly interacts with, and phosphorylates IκBα at Ser-32.

Conclusion: TOPK is a critical mediator of cervical cancer chemoresistance in response to doxorubicin

Significance: This study provides new insight on role of TOPK in cervical cancer cells survival in response to doxorubicin

SUMMARY

T-lymphokine-activated killer cell-originated protein kinase (TOPK) is known to be upregulated in cancer cells, and appears to contribute to cancer cells proliferation and survival. However, the molecular mechanism by which TOPK regulates cancer cells survival still remains elusive. Here we show that TOPK directly interacted with, and phosphorylated IκBα at Ser-32 leading to p65 nuclear translocation and NF-κB activation. We also revealed that doxorubicin promoted the interaction between non-phosphorylated or phosphorylated TOPK and IκBα, and that TOPK-mediated IκBα phosphorylation was enhanced in response to doxorubicin. Also, exogenously overexpressed TOPK augmented transcriptional activity driven by either NF-κB or inhibitor of apoptosis protein 2 (cIAP2) promoters. On the other hand, NF-κB activity including IκBα phosphorylation and p65 nuclear translocation, as well as cIAP2 gene expression was markedly diminished in TOPK knockdown HeLa cervical cancer cells. Moreover, doxorubicin-mediated apoptosis was noticeably increased in TOPK knockdown HeLa cells, compared with control cells, which resulted from caspase-dependent signaling pathways. These results demonstrate that TOPK is a molecular target of doxorubicin and mediates doxorubicin chemoresistance of HeLa cells, suggesting a novel mechanism for TOPK barrier of doxorubicin-mediated cervical cancer cell apoptosis.

Doxorubicin, anthracycline antibiotic, is known to function as a potent chemotherapeutic agent against solid tumors and malignant hematological diseases (1, 2). Doxorubicin acts as DNA intercalating agent, causing dysfunction of DNA topoisomerase II and double-stranded DNA break, and elicits its inhibitory activity on tumors (3). This doxorubicin-induced DNA
Role of TOPK in HeLa cancer cells resistance to doxorubicin-mediated apoptosis

damage leads to target cell death. In parallel, DNA damage results in NF-κB activation to enhance transcription of NF-κB-driven genes, which are involved in cell proliferation and survival (4). In unstimulated state, NF-κB is sequestered in the cytoplasm by binding to IκB. In response to doxorubicin, IκB kinases (IKKs) complex comprised of IKKα, IKKβ, and NEMO, is activated and phosphorylates IκB which is sequentially ubiquitinated and subjected to proteasomal degradation (5). NF-κB is then released from IκB, and activated NF-κB enters into nucleus and induces target gene transcription. Previous studies show that doxorubicin-induced apoptosis is triggered by cascades of caspase activation (6, 7). NF-κB is shown to play an important role in maintaining resistance to doxorubicin-induced tumor cells apoptosis, and to contribute to prevention of efficacy of cancer therapeutics (8, 9). Indeed, inhibition of NF-κB sensitizes tumor cells to apoptosis in response to doxorubicin (10, 11).

T-LAK-cell-originated protein kinase (TOPK) is known to be a serine/threonine kinase that is highly expressed in various malignant cells such as Burkitt’s lymphoma and hematopoietic neoplasms or in normal tissues including testis, kidney, lung, placenta, and embryonic tissues (12-16). It has been proposed that TOPK, MAPKK-like protein kinase, acts as an upstream kinase for p38 mitogen-activated protein kinase (MAPK), phosphatase MKP1, and peroxiredoxin 1 (Prx1) (12, 17, 18). In addition, TOPK phosphorylates c-Jun N-terminal kinase 1 (JNK1) in UVB-mediated signaling or ras-induced cell transformation, and positively regulates extracellular signal-regulated kinase 2 (ERK2) during tumorigenesis (19, 20). The cyclin B1/Cdk1 binds and phosphorylates TOPK on Thr9 residue during mitosis, leading to enhance cytokinesis through PRC1 phosphorylation (13, 21). It was reported that TOPK associates with p53 and suppresses its transcriptional activity, resulting in reduction of p21 expression (22). Previously, we showed that TOPK confers TRAIL resistance to cancer cells (23). These reports suggest a role for TOPK in cancer cell proliferation and survival. However, little is known about mechanisms regarding role of TOPK in cancer cell survival against cancer chemotherapy drugs involving doxorubicin.

Here we reveal that TOPK is a novel target molecule in response to doxorubicin, and that TOPK directly interacts with, and phosphorylates IκBα at Ser-32, leading to subsequent NF-κB activation. We also demonstrate that depletion of endogenous TOPK abrogated doxorubicin-induced IκBα phosphorylation or p65 nuclear translocation. We provide evidence that overexpressed TOPK upregulated expression of cIAP2 gene, one of NF-κB-dependent antiapoptotic genes and conferred resistance to doxorubicin-induced HeLa cervical cancer cell death.

EXPERIMENTAL PROCEDURES

Cells and reagents- Human embryonic kidney 293 cells, Chinese Hamster Ovary (CHO)-K1, and Human HeLa cervical cancer cells were purchased from American Type Culture Collection (ATCC). Each cell line was maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1% penicillin/streptomycin. Doxorubicin hydrochloride, wedelolactone, SB202190, SP600125, U0126 or β-actin antibody was purchased from Sigma (St. Louis, MO). DeadEnd fluorometric TUNEL System and luciferase assay system were from Promega (Madison, WI). Tubulin or IκBα antibody or protein A/G plus-agarose bead was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). V5 antibody or SuperScript III reverse transcriptase was from Invitrogen (Grand Island, NY), respectively. Antibodies against caspase 3, caspase 8, cleaved PARP (Asp214), p-AKT (Ser-473), p65, IκBα (sepharose bead conjugate) and p-IκBα (Ser-32) were from Cell Signaling Technology, Inc. (Beverly, MA). Antibody against TOPK or p-serine/threonine was from Abcam (Cambridge, MA). Active or inactive GST-TOPK protein was from SignalChem (Richmond, BC), respectively. Transfection reagent Effectene was from Qiagen, Inc. (Valencia, CA). Z-VAD-FMK, Z-IETD-FMK or
GST-\(\kappa B\)\(\alpha\) protein was from EMD Millipore (Billerica, MA). Glutathione Sepharose 4B was from GE Healthcare Biosciences (Pittsburgh, PA).

**Plasmids and transfection**- Plasmid V5-TOPK was constructed. Briefly, total RNA from HeLa cell was extracted, and cDNA was prepared using Superscript III reverse transcriptase (Invitrogen). Sequentially, PCR was performed with the cDNA using sense strand, 5' - CGCGGATCCGATGGAAGGGATCA-3' harboring BamHI site and antisense strand, 5' - CCGCTCGAGCGGGACATCTGTTTCCAGGCTT-3' harboring XhoI site, and the PCR product cut with BamHI/XhoI was inserted into the BamHI/XhoI sites of pcDNA6/V5-His A (Invitrogen). The construct was verified by sequencing. Plasmids, cIAP2 promoter-driven luciferase reporter vectors, wild type and NF-\(\kappa B\) mutants, were kindly provided by Dr. Hinrich Gronemeyer (24). GFP-p65/RelA construct was kindly gift from Dr. Warner C. Greene (25). NF-\(\kappa B\)-dependent luciferase vector and TOPK siRNA construct were as described previously (23). 293 or HeLa cells growing on 100mm dish was transfected with each 10 \(\mu\)g of plasmids using Effectene according to manufacturer’s instructions. 24 hr after transfection, cells were lysed, and cell lysate was subjected to immunoblot or immunoprecipitation.

**In vitro kinase assay**- In vitro kinase assay was performed with active or inactive TOPK and GST-\(\kappa B\)\(\alpha\) protein. Briefly, the reactions containing 100 \(\mu\)M were done at 30°C for 30 min. The samples were subjected to 10% SDS-PAGE and visualized by immunoblot. TOPK immunoprecipitation kinase assay, 293 cells were transfected with V5-TOPK construct, treated with doxorubicin, and lysed. Cell lysate was immunoprecipitated with V5 antibody. The precipitates were reacted with GST-\(\kappa B\)\(\alpha\), and analyzed with immunoblot using phospho-\(\kappa B\)\(\alpha\) (Ser-32) antibody.

**Immunoblot and immunoprecipitation**- For immunoblot analysis, 20 \(\mu\)g of each total cell lysate was resolved by SDS-PAGE, probed using each respective antibody, and detected with SuperSignal west pico chemiluminescent substrate (Pierce Biotechnology, Inc., Rockford, IL) and X-ray film. For immunoprecipitation, 500 \(\mu\)g of total cell lysate was mixed with specific antibody and then protein agarose beads at 4°C for 2 hr using rocker. The beads were washed, subjected to 10% SDS-PAGE, and then immunoblot.

**GST pull down assay**- To investigate the interaction of TOPK and \(\kappa B\)\(\alpha\), GST pull down assay was performed with GST-\(\kappa B\)\(\alpha\). 293 cells were expressed with V5-TOPK construct, harvested 24 hr after transfection, and lysed. 500 \(\mu\)g of total cell lysate was incubated with 2 \(\mu\)g of GST-\(\kappa B\)\(\alpha\) protein coupled to Glutathione Sepharose 4B at 4°C for 2 hr. The beads were washed with lysis buffer, boiled with sample buffer, separated on 10% SDS-PAGE, and then analyzed with immunoblot using V5 antibody.

**Luciferase assay**- For luciferase assay, CHO-K1 cells growing on six well plates were transfected with each 1 \(\mu\)g of NF-\(\kappa B\) promoter or cIAP2 promoters-luciferase reporter construct, plus 0.5 \(\mu\)g of the pRL-SV40 gene using 4 \(\mu\)l of Effectene reagent. 24 hr after transfection, cells were treated with doxorubicin for 24 hr, harvested, and then lysed. Firefly and Renilla luciferase activities were measured using cell lysate.

**Reverse transcription –PCR**- Total RNAs were prepared from control siRNA cells or HeLa-TOPK siRNA cells using TRIzol reagent (Invitrogen). Reverse transcription-PCR was done using SuperScript III reverse transcriptase (Invitrogen) and PCR master mix (Qiagen). PCR was carried out for 1 cycle at 95°C for 15 min, and 28 cycles at 95°C for 30 s, 55°C for 30 s, and 68°C for 1 min. Each primer is as follows. c-IAP2 (forward), 5'-CTTTGCTGTGGGAAAT-3'; c-IAP2 (reverse), 5'-ACTTGCAAGCTGCTCAGGAT-3'; GAPDH (forward), 5'-GACTCATGACCAGGATGC-3'; GAPDH (reverse), 5'-AGAGCCAGGATGTTTCTG-3'. PCR
products were separated on a 1.5% agarose gel and analyzed with GelDoc (Biorad).

**GFP-RelA localization-** Control siRNA cells or HeLa-TOPK siRNA cells were seeded on cover glass in six-well plates and transfected with 0.5 μg of GFP-RelA construct. Cells were stimulated with doxorubicin for 6 hr. Cells were observed under a fluorescent microscope to determine expression and localization of GFP-RelA.

**Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay-** TUNEL assay was performed using DeadEnd fluorometric TUNEL system (Promega) according to manufacturer’s instruction. Control siRNA cells or HeLa-TOPK siRNA cells were treated with doxorubicin for 24 hr, fixed with 4% methanol-free formaldehyde, permeabilized with Triton X-100. Terminal deoxynucleotidyltransferase and nucleotide mixture including fluorescein-dUTP were used for labeling DNA breaks. After incubation, cells were washed and mounted. Cells were observed and analyzed under a fluorescence microscope.

**Statistical analysis-** Results are shown as the mean ± SD for at least three independent experiments in duplicates. Significant differences were evaluated by student’s t test.

**RESULTS**

**Doxorubicin activates TOPK and promotes association of TOPK with IκBα-** Little is known about signaling effectors of TOPK, including upstream kinases, downstream substrates, or stimuli. Doxorubicin commonly used in cancer treatment is known to induce genotoxic stress and p53 activation (26). However, the molecular targets of doxorubicin are poorly characterized. We have explored whether doxorubicin can affect TOPK activity or expression. To investigate whether doxorubicin might affect TOPK activity, we first treated human cervical HeLa cancer cells with doxorubicin in time-dependent manner. Results showed that doxorubicin strongly induced phosphorylation of serine and threonine (Ser/Thr) residues on TOPK, indicating efficacy of doxorubicin on catalytic activity of TOPK (Fig. 1A). TOPK expression was little affected by doxorubicin treatment. We next examined change of phosphorylation level of IκBα or AKT that is involved in cancer cell survival. Phosphorylation level of IκBα or AKT was augmented at 1 or 2 hr after doxorubicin treatment. These results suggest that TOPK might be one of molecular targets of doxorubicin, and that doxorubicin-induced TOPK activity might be implicated in IκBα phosphorylation. We next hypothesized that TOPK could associate with, and regulate IκBα phosphorylation status. To examine the possibility for binding of TOPK to IκBα, we transfected V5-TOPK into HEK293 cells, and left them in the absence or presence of doxorubicin, and then performed immunoprecipitation experiments. We discovered that TOPK directly bound to IκBα in vivo and doxorubicin markedly enhanced the binding capacity (Fig. 1B). To further verify that TOPK interacts with IκBα in vitro, GST pull-down assays were also carried out. GST-IκBα coupled to glutathione-Sepharose beads was incubated with cell lysate expressing V5-TOPK construct. Results indicated that TOPK bound to IκBα in vitro, proving a direct interaction between TOPK and IκBα (Fig. 1C). Furthermore, we verified that endogenous TOPK associated with IκBα and the interaction was significantly potentiated by doxorubicin treatment (Fig. 1D). To ensure that phosphorylated TOPK is indeed active form of TOPK, we also explored whether phosphorylated TOPK interacts with IκBα. The phosphorylated TOPK at Thr-9 was shown to bind to IκBα (Fig. 1E). The binding was markedly increased in response to doxorubicin. Collectively, these findings demonstrated that TOPK interacts with IκBα, and that doxorubicin induces TOPK phosphorylation and promotes association of phosphorylated TOPK with IκBα, probably affecting IκBα phosphorylation.
Role of TOPK in HeLa cancer cells resistance to doxorubicin-mediated apoptosis

**TOPK directly phosphorylates IκBα and doxorubicin enhances its kinase activity.** We next examined whether TOPK could phosphorylate IκBα. The active form of TOPK, a constitutively phosphorylated TOPK at Thr-9, was employed for kinase assay. Kinase assay using active TOPK and GST-IκBα was performed in vitro. Results revealed that active TOPK phosphorylated serine 32 (Ser-32) residue on IκBα in dose-dependent manner (Fig. 2A). As expected, inactive TOPK did not exert the kinase activity against IκBα (Fig. 2B). We also investigated whether doxorubicin affects TOPK-induced IκBα phosphorylation in vivo. V5-TOPK construct was expressed in HEK293 cells, and then followed by immunoprecipitation kinase assay. We confirmed that doxorubicin strongly induces TOPK-mediated phosphorylation of IκBα (Ser-32) in time-dependent manner (Fig. 2C). These results suggest that TOPK associates with, and directly phosphorylates IκBα to elicit NF-κB activity.

**TOPK positively regulates NF-κB-driven transcriptional activity and cIAP2 gene expression in response to doxorubicin.** Doxorubicin has been reported to induce NF-κB activation in apoptosis process (27). We asked whether TOPK can be involved in doxorubicin-induced NF-κB-responsive transcriptional activity. CHO-K1 cells were transfected with NF-κB promoter-driven luciferase reporter construct without or with V5-TOPK construct, and then left in absence or presence of doxorubicin. As expected, NF-κB promoter-driven transcriptional activity was augmented by doxorubicin treatment (Fig. 3A). Also, expression of TOPK alone increased the transcriptional activity in dose-dependent manner. Moreover, doxorubicin-induced NF-κB activity was markedly increased by TOPK expression. We next employed promoter of cIAP2 gene, one of NF-κB responsive genes, which is linked to luciferase reporter gene. Using promoters of wild type or NF-κB cis-element mutant types of cIAP2, transcriptional activities were assessed. As shown in Fig. 3B, TOPK expression resulted in increase of cIAP2 promoter-driven luciferase activity induced by doxorubicin, whereas the activity was greatly reduced in cIAP2 promoters having mutation on NF-κB cis-element. It appeared that cIAP2 promoter (-39 mut) having mutation of a NF-κB site (-39) elicited a little differential responsiveness compared with another cIAP2 promoter (+102 mut), indicating site-specific selectivity of NF-κB response. We have previously established HeLa-TOPK siRNA knockdown cell lines (23). Using reverse transcription-PCR experiment, we next investigated whether TOPK affects expression of cIAP2 gene in response to doxorubicin. Doxorubicin strongly induced expression of cIAP2 gene in control cells (Fig. 3C). In contrast, the doxorubicin-induced cIAP2 gene expression was dramatically diminished in TOPK siRNA cells. As expected, doxorubicin treatment also increased the expression of TOPK gene. Taken together, these findings demonstrate that TOPK upregulates NF-κB activity and cIAP2 expression in response to doxorubicin, implying the role of TOPK in doxorubicin-mediated apoptotic signaling.

**Depletion of TOPK abolishes doxorubicin-mediated IκBα phosphorylation and p65 nuclear translocation.** Doxorubicin has been suggested to induce IκB phosphorylation and p65 nuclear translocation (28). To clarify the effect of TOPK on doxorubicin-mediated IκBα degradation or phosphorylation, we employed HeLa-TOPK siRNA knockdown cell lines. As expected, the phosphorylation level of IκBα in HeLa cells expressing control siRNA was markedly augmented in response to doxorubicin treatment, whereas the level was little changed in TOPK siRNA cells (Fig. 4A). We also determined the effect of wedelolactone, irreversible inhibitor of IKKα and IKKB, on doxorubicin-induced IκBα phosphorylation. Wedelolactone little affected the doxorubicin-induced IκBα phosphorylation. These data imply that TOPK-mediated IκBα phosphorylation in response to doxorubicin might be independent on IKKs. In response to various stimuli including doxorubicin, p65/RelA nuclear translocation is essential for NF-κB activation. Cells were transfected with GFP-RelA construct and treated with doxorubicin,
Role of TOPK in HeLa cancer cells resistance to doxorubicin-mediated apoptosis

and then analyzed by fluorescence microscopy. In control siRNA cells, RelA was shown to be successfully translocated to nucleus in response to doxorubicin (Fig. 4B). In contrast, RelA failed to displace from cytoplasm to nucleus in TOPK siRNA cells by doxorubicin. Also, the level of RelA protein in cytoplasm or nucleus was assessed. Nuclear RelA was markedly increased in response to doxorubicin in control siRNA cells (Fig. 4C), whereas the nuclear RelA was a little increased in TOPK siRNA cells. On the other hand, basal level of nuclear RelA in absence of doxorubicin is decreased in TOPK siRNA cells, compared to control siRNA cells, suggesting TOPK-mediated basal regulation of nuclear p65 expression. Collectively, these findings propose that TOPK mediates IkBα phosphorylation and subsequent RelA nuclear translocation in response to doxorubicin as well as regulation of basal expression of nuclear p65.

TOPK confers resistance to doxorubicin-induced HeLa cancer cells apoptosis- We next asked that TOPK might contribute to HeLa cervical cancer cell chemoresistance in response to doxorubicin. Therefore, we explored effect of knocking down of TOPK on doxorubicin-induced cell death. Doxorubicin-induced apoptosis rate in control siRNA cells was reduced about 29%, compared to the rate in HeLa-TOPK siRNA cells (Fig. 5A). To examine whether endogenous TOPK affected doxorubicin-mediated caspases activation leading to PARP cleavage, activation of caspase 3 or caspase 8 as well as PARP were examined in TOPK siRNA or control siRNA cells. Cleaved forms of caspase 3 or caspase 8 were more increased by doxorubicin treatment in TOPK siRNA cells than control siRNA cells (Fig. 5B). Also, cleaved forms of PARP were more increased in TOPK siRNA cells. These results demonstrate that endogenous TOPK alleviates doxorubicin-induced caspase 8 and caspase 3 activation, leading to PARP inactivation, suggesting the role of TOPK in doxorubicin-induced HeLa cancer cells apoptosis. To ensure that doxorubicin-induced apoptosis in HeLa-TOPK siRNA cells is mediated via caspase activation pathway, two inhibitors, general caspase inhibitor Z-VAD-FMK, and caspase 8 inhibitor Z-IETD-FMK, were employed. As expected, cleaved forms of PARP were decreased in the presence of each inhibitor, together with doxorubicin (Fig. 5C). These data show that doxorubicin-induced apoptosis in TOPK siRNA cells is mediated via caspase activation pathway. On the other hand, MAPK signaling pathways including ERK, p38 and JNK have been suggested to be implicated in doxorubicin-induced cancer cells apoptosis (29, 30). Therefore, we next asked whether MAPK pathways are involved in doxorubicin-induced apoptosis in HeLa-TOPK siRNA cells. Using specific inhibitors such as MEK1/2 inhibitor U0126, p38MAPK inhibitor SB202190, or JNK inhibitor SP600125, effect of doxorubicin on PARP cleavage in TOPK siRNA cells was determined. Treatment of SP600125, but not U0126 and SB202190, blocked doxorubicin-induced PARP cleavage (Fig. 5D). These results indicate that JNK might play an important role in doxorubicin-induced HeLa cells, especially TOPK-depleted cells killing.

DISCUSSION

It has been suggested that some stimuli including TPA or UVB positively regulate TOPK activity (12, 17, 19). However, information about signaling pathways or stimuli triggering TOPK activation still lacks. In this study, we uncovered that doxorubicin, one of anticancer drugs, could phosphorylate serine or threonine residues on TOPK, and increases TOPK mRNA level, indicating the effect of doxorubicin on TOPK catalytic activity and TOPK gene expression. Although action mechanism of doxorubicin in cancer cell apoptosis is known, the molecular targets of doxorubicin are poorly identified. We here demonstrated that TOPK functions as a novel target molecule of doxorubicin, implying a critical role of TOPK in doxorubicin-induced cervical cancer cell death. Some molecules such as p38MAPK, JNK, phosphatase MKP1, and peroxiredoxin 1 (Prx1) have been proposed to act as downstream substrates for TOPK (12, 17-19). However, evidences for downstream targets of TOPK still remain elusive. We identified that...
TOPK directly binds to IκBα, and phosphorylates serine-32 residue on IκBα in response to doxorubicin leading to NF-κB activation. These data define TOPK as an upstream kinase of IκBα regulating NF-κB activity with a possible role in doxorubicin-mediated cervical cancer cell apoptosis. It has been suggested that NF-κB contributes to chemoresistance to anticancer drugs and is triggered by genotoxic agents including doxorubicin, which limit chemotherapeutics-mediated anticancer effects (31). Also, NF-κB activation is known to result in induction of survival factors, Bcl-2 or IAPs (32). Therapeutic approaches to overcome NF-κB-mediated chemoresistance are closely implicated in induction of IκB overexpression or IκB stabilization via proteasome inhibition preventing IκB degradation (33, 34). In this study, endogenously overexpressed TOPK was shown to increase doxorubicin-mediated NF-κB driven transcriptional activity in HeLa cervical cancer cells. The findings that TOPK activates NF-κB in response to doxorubicin revealed the role of TOPK as a critical mediator in cervical cancer cell survival. Previous report proposed that NF-κB activity induced by ultraviolet radiation or chemotherapeutic agents-induced DNA damage might promote U2OS osteosarcoma cell death, associated with interaction of p65 and histone deacetylases (35). Recent study also showed that doxorubicin increased transcription of cIAP2 gene, one of antiapoptotic genes, but repressed expression of Bcl-xL, XIAP, Bcl-2 or survivin gene in U2OS osteosarcoma cells, and that NF-κB inhibition prevented doxorubicin-mediated transcription of cIAP2, leading to enhancing cell death (27). Agreeing with this result, we indicated that expression of cIAP2 gene is increased in HeLa cervical cancer cells by doxorubicin treatment, but TOPK depletion abolishes this augmentation via NF-κB inhibition. These findings suggest that doxorubicin-mediated increment of cIAP2 gene transcripts might be dependent on endogenous TOPK expression and that the reduction of cIAP2 via NF-κB inhibition promotes cervical cancer cell death. It has been proposed that some MAPKs or their related signaling pathways are implicated in chemotherapeutics-mediated apoptosis (36-38). Especially, JNK activity is closely involved in apoptosis in response to chemotherapeutic agents involving doxorubicin (7, 30, 39), which results in release of mitochondrial cytochrome c and SMAC to cytoplasm, leading to caspase activation. Proapoptotic 9 is recruited and activated with subsequent activation of the downstream effector caspase-3 and PARP (40). Inhibition of JNK, but not ERK and p38MAPK markedly prevents doxorubicin-mediated apoptosis of TOPK-depleted HeLa cervical cancer cells. This finding suggests that JNK activity is essential for apoptosis to doxorubicin in cervical cancer cell lacking endogenous TOPK. Therefore, Approach to efficient doxorubicin-mediated chemotherapy for cervical cancers might include in part JNK activation as well as blockage of TOPK expression or activity. Taken together, this study demonstrates that doxorubicin activates TOPK’s interaction with IκBα and promotes its kinase activity against IκBα at Ser-32, leading to NF-κB activation. Also, we provide evidence that TOPK augments expression of cIAP2, acting as a key survival mediator in doxorubicin-mediated apoptotic pathway, conferring resistance to doxorubicin-induced HeLa cervical cancer cell death. We here suggest that TOPK is a critical mediator of cervical cancer chemoresistance in response to doxorubicin. Therefore, approaches to inhibit TOPK through blocking its expression or its kinase activity via development of pharmacologic inhibitor might be valuable for further investigation involving mechanistic research to overcome cervical cancer chemoresistance and enhance chemosensitization.
REFERENCES


Role of TOPK in HeLa cancer cells resistance to doxorubicin-mediated apoptosis

expression by RelA(p65) NF-kappa B. *Mol Cell* **13**, 853-865


Role of TOPK in HeLa cancer cells resistance to doxorubicin-mediated apoptosis

Acknowledgments—We thank laboratory members for critical reading of the manuscript.

FOOTNOTES

*This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0005899). This work was supported in part by Konyang University Myunggok Research Fund of 2009.

To whom correspondence may be addressed: Department of Biochemistry, College of Medicine, Konyang University, 685 Gasuwon-dong, Seo-gu, Daejeon 302-718, Korea. Phone: +82-42-600-6454; Fax: +82-42-600-6450; E-mail: sangmuk_oh@konyang.ac.kr

The abbreviations used are: NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; IκBα, Inhibitor of kappa light chain gene enhancer in B cells alpha; cIAP2, inhibitor of apoptosis 2; siRNA, small interfering RNA; IKK, IκB kinase; PCR, polymerase chain reaction; PARP, Poly (ADP-ribose) polymerase; Bcl-xL, B-cell lymphoma-extra large; JNK, c-Jun N-terminal kinase, MAPK, mitogen-activated protein kinase; ERK, extracellular-signal-regulated kinase, MEK, Mitogen activated protein kinase kinase; SMAC, Second mitochondria derived activator of caspase.

These authors contributed equally to this work.

FIGURE LEGENDS

FIGURE 1. TOPK is activated by doxorubicin and directly associates with IκBα. A. HeLa cells were stimulated with 1 μM of doxorubicin (Dox) for each indicated time. Each cell lysate (500 μg) was immunoprecipitated with TOPK antibody (1 μg), and followed by immunoblotting using phosphoserine/threonine (p-Ser/Thr) antibody. Phosphorylation of indicated proteins was detected with the respective phospho-specific antibodies. B. 293 cells grown on 100 mm dishes were transfected with each 10 μg of empty vector or V5-TOPK construct. At 24 h after transfection, cells were treated with doxorubicin (1 μM) for each indicated time. Each cell lysate (500 μg) was subjected to immunoprecipitation using IκBα antibody (1 μg), and then analyzed by immunoblot using V5 antibody. Expression of V5-TOPK was verified. C. Each 10 μg of Empty vector or V5-TOPK construct was expressed in 293 cells and GST pull down experiment was done using cell lysate (500 μg) and GST-IκBα (2 μg) coupled to glutathione-Sepharose beads. The beads were subjected to 10% SDS-PAGE, and then probed with V5 antibody. D. HeLa cells were treated with 1 μM of doxorubicin (Dox) for each indicated time. Immunoprecipitation was done with IκBα antibody (sepharose bead conjugate), and followed by immunoblot using TOPK or IκBα antibody. E. Each 10 μg of V5-TOPK construct was expressed in 293 cells. Cells were treated with doxorubicin (1 μM) for each indicated time. Each cell lysate (500 μg) was immunoprecipitated using IκBα antibody (sepharose bead conjugate), and then probed with phospho-TOPK (Thr9) antibody.

FIGURE 2. TOPK phosphorylates IκBα at Ser-32. A. in vitro kinase assay was performed with GST-IκBα (0.5 μg) and each active TOPK (25, 50, 100 ng). After 30 min incubation at 30°C, reaction mixture was subjected to 10% SDS-PAGE and immunoblot using phospho-IκBα (Ser-32) antibody. B. TOPK kinase assay was done using active or inactive TOPK (each 100 ng). The phosphorylated IκBα was detected with phospho-specific antibody recognizing Ser-32 residue on IκBα. C. 293 cells were transfected with V5-TOPK or empty vector. At 24 hr post-transfection, cells were treated with...
doxorubicin (1 μM) for 2 or 4 hr, and cell lysate was immunoprecipitated with V5 antibody. The immunoprecipitation kinase assay was performed using GST- IκBα (0.5 μg).

FIGURE 3. TOPK promotes doxorubicin-induced NF-κB activity and cIAP2 transcriptional activity. A. CHO-K1 cells grown on six-well plates were transfected with NF-κB-luciferase construct (1 μg) and each indicated V5-TOPK construct (1, 2, 4 μg), together with 0.1 μg of pRL-SV40 gene. 24 hr after transfection, cells were treated or not treated with doxorubicin (1 μM) for 6 hr. Luciferase activity was measured using cell lysate. Firefly luciferase activity was normalized against Renilla luciferase activity. *, p<0.01, **, p<0.05 B. CHO-K1 cells grown on six-well plates were transfected with each wild type (WT) or mutant (-39 and +102) cIAP2 promoter driven luciferase construct (1 μg) and V5-TOPK construct (1 μg), together with 0.1 μg of pRL-SV40 gene. At 24 hr posttransfection, cells were stimulated with doxorubicin (1 μM) for 6 hr. Luciferase activity was evaluated. *, p<0.01, **, p<0.05 C. Total RNAs were prepared from HeLa-TOPK siRNA or control siRNA cells stimulated with doxorubicin (1 μM). RT-PCR was sequentially performed using SuperScript III reverse transcriptase and each primer for cIAP2 or GAPDH genes. PCR products were resolved on a 1.5% agarose gel and analyzed using GelDoc (Biorad).

FIGURE 4. Ablation of TOPK blocks IκBα phosphorylation and p65 nuclear translocation in response to doxorubicin. A. HeLa-TOPK siRNA cells or control siRNA cells were treated with doxorubicin (1 μM) for indicated time in the presence or absence of wedelolactone (10 μM). Amount of phosphorylated IκBα, TOPK or Tubulin proteins was assessed with the respective antibodies. B. TOPK siRNA cells or control siRNA cells grown on cover glass were transfected with GFP-RelA. At 24 hr posttransfection, cells were stimulated with doxorubicin (1 μM) for 6 hr. Cells mounted on slide glass were observed with fluorescent microscope. The nuclei were stained with DAPI and representative photos of at least 3 independent experiments are shown. C. TOPK siRNA cells or control siRNA cells were incubated with doxorubicin (1 μM) for indicated time. Cells were harvested, and cytoplasmic extract (C) or nuclear extract (N) was prepared. The p65 level was evaluated using immunoblot analysis. ImageJ software was used for quantification.

FIGURE 5. TOPK confers resistance to doxorubicin-mediated HeLa cancer cell apoptosis. A. HeLa-TOPK siRNA cells or control siRNA cells on cover glass were treated with doxorubicin (1 μM) for 24 hr. TUNEL assay was employed for apoptosis analysis. Cells were observed by immunofluorescence microscopy. The percentage of dead cells was estimated by calculating dead cells and live cells (300 cells minimum). Representative images of at least 3 independent experiments are indicated. B. TOPK siRNA cells or control siRNA cells were incubated with doxorubicin (1 μM) for 24 hr. The level of cleaved caspase 8, caspase 3, and PARP was indicated. C. TOPK siRNA cells were stimulated with doxorubicin (1 μM) in the presence or absence of each 20 μM of Z-VAD-FMK or Z-IETD-FMK. Cleaved PARP level was shown. D. TOPK siRNA cells were treated with doxorubicin (1 μM) in the presence or absence of each 10 μM of SB202190, SP600125 or U0126. The amount of cleaved PARP was indicated.
Figure 1

A

Dox (1 µM) - 1 2 6 hr

36- p-TOPK
IP: α-TOPK, IB: α- p-Ser/Thr

36- p-ΙκBα
IB: α- p-ΙκBα (Ser-32)

55- p-AKT
IB: α- p-AKT (Ser-473)

36- TOPK
IB: α-TOPK

36- β-actin
IB: β-actin

Cell lysate

B

V5-TOPK - + + +

Dox (1 µM) - - 1 2 6 hr

55- TOPK
IP: α-ΙκBα, IB: α-V5

36- V5

36- β-actin
IB: β-actin

Cell lysate

C

V5-TOPK - - + +

GST-ΙκBα - + - +

36- V5-TOPK

GST pull down, IB: α-V5

36- V5-TOPK
IB: α-V5

36- β-actin
IB: β-actin

Cell lysate

D

Dox (1 µM) - 1 2 6 hr

55- TOPK
IP: α-ΙκBα, IB: α-TOPK

36- ΙκBα
IP: α-ΙκBα, IB: α-ΙκBα

36- TOPK
IB: α-TOPK

36- β-actin
IB: β-actin

Cell lysate

E

V5-TOPK + + + +

Dox (1 µM) - 1 2 6 hr

55- p-TOPK
IP: α-ΙκBα, IB: α-p-TOPK (Thr9)

36- V5-TOPK
IB: α-V5

36- β-actin
IB: β-actin

Cell lysate

Cell lysate
Figure 2

A

Active TOPK
GST-\(\kappa\)B\(\alpha\)

+       -       +       +       +

TOPK kinase assay, \(\text{IB: } \alpha\)-p-\(\kappa\)B\(\alpha\) (Ser-32)

Input

IB: \(\alpha\)-\(\kappa\)B\(\alpha\)

72
55

IB: \(\alpha\)-TOPK

72
55

72
55

GST-\(\kappa\)B\(\alpha\)

\(\uparrow\)

GST-TOPK

\(\uparrow\)

B

Inactive TOPK
Active TOPK
GST-\(\kappa\)B\(\alpha\)

-       -       +       -        +

TOPK kinase assay, \(\text{IB: } \alpha\)-p-\(\kappa\)B\(\alpha\) (Ser-32)

Input

IB: \(\alpha\)-\(\kappa\)B\(\alpha\)

72
55

IB: \(\alpha\)-TOPK

72
55

72
55

GST-\(\kappa\)B\(\alpha\)

\(\uparrow\)

GST-TOPK

\(\uparrow\)

C

Dox (1 \(\mu\)M)  -       -  2  6 hr
V5-TOPK  -       +       +       +
GST-\(\kappa\)B\(\alpha\)  +       +       +       +

\(\text{IP: } \alpha\)-V5, TOPK kinase assay

\(\text{IB: } \alpha\)-p-\(\kappa\)B\(\alpha\) (Ser-32)

\(\text{IB: } \alpha\)-TOPK

\(\text{IB: } \alpha\)-V5

\(\text{IB: } \beta\)-actin
Figure 3

A

Dox (1 µM)        -           +              -           +
V5-TOPK           -           -              +           +

Relative Luciferase Activity

B

Dox (1 µM)       -     +    -     +    -     +    -     +    -     +
V5-TOPK         -      -    +    +    -     -     +    +    -     -    +    +

Relative Luciferase Activity

C

Dox (1 µM)

control siRNA        TOPK siRNA

clAP2
TOPK
GAPDH
Figure 4

A

<table>
<thead>
<tr>
<th>Dox (1 µM)</th>
<th>Control siRNA</th>
<th>TOPK siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Wedelolactone (10 µM)</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>6</td>
</tr>
</tbody>
</table>

IB: α–p-IκBα (Ser-32)

IB: α–TOPK

IB: α–Tubulin

B

Control siRNA

<table>
<thead>
<tr>
<th>Dox (1 µM)</th>
<th>GFP-RelA</th>
<th>DAPI</th>
<th>merge</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TOPK siRNA

<table>
<thead>
<tr>
<th>Dox (1 µM)</th>
<th>GFP-RelA</th>
<th>DAPI</th>
<th>merge</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

Control siRNA

<table>
<thead>
<tr>
<th>Dox (1 µM)</th>
<th>Control siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>N</td>
</tr>
<tr>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td></td>
</tr>
</tbody>
</table>

IB: α–p65

IB: α–Tubulin

TOPK siRNA

<table>
<thead>
<tr>
<th>Dox (1 µM)</th>
<th>TOPK siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>N</td>
</tr>
<tr>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td></td>
</tr>
</tbody>
</table>

IB: α–p65

IB: α–Tubulin
Figure 5

A

Dox (1 µM) | TUNEL | DAPI | merge
---|---|---|---
Control siRNA | ![Control siRNA](image1) | ![Control siRNA](image2) | ![Control siRNA](image3) | 23%
TOPK siRNA | ![TOPK siRNA](image4) | ![TOPK siRNA](image5) | ![TOPK siRNA](image6) | 52%

B

Dox (1 µM) | Control siRNA | TOPK siRNA
---|---|---
- | + | - | +
- | + | - | +
- | + | - | +
- | + | - | +

IB: α-caspase 3
IB: α-caspase 8
IB: α-cleaved PARP
IB: α-TOPK
IB: α-Tubulin

C

Dox (1 µM) | DMSO | Z-VAD-FMK | Z-IETD-FMK
---|---|---|---
- | + | - | +
- | + | - | +
- | + | - | +
- | + | - | +

IB: α-cleaved PARP (Asp 214)
IB: α-TOPK
IB: β-actin

D

Dox (1 µM) | DMSO | SB202190 | SP600125 | U0126
---|---|---|---|---
- | + | - | + | -
- | + | - | + | -
- | + | - | + | -
- | + | - | + | -

IB: α-cleaved PARP (Asp 214)
IB: α-TOPK
IB: β-actin
Phosphorylation of IκBα at Ser-32 by TOPK is essential for chemoresistance against doxorubicin in cervical cancer cells
Jung-Hwan Park, Dae-Sung Yoon, Hye-Jin Choi, Dae-Hyun Hahm and Sang-Muk Oh
J. Biol. Chem. published online December 17, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.422170

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

This article cites 0 references, 0 of which can be accessed free at http://www.jbc.org/content/early/2012/12/17/jbc.M112.422170.full.html#ref-list-1